Strs Ohio Invests $1 Million in Sotera Health Company $SHC

Strs Ohio acquired a new stake in Sotera Health Company (NASDAQ:SHC) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 85,997 shares of the company’s stock, valued at approximately $1,003,000.

Several other institutional investors and hedge funds also recently made changes to their positions in SHC. TPG GP A LLC acquired a new position in shares of Sotera Health in the first quarter valued at approximately $79,126,000. Sculptor Capital LP increased its stake in shares of Sotera Health by 80.8% in the first quarter. Sculptor Capital LP now owns 9,037,511 shares of the company’s stock valued at $105,377,000 after buying an additional 4,037,511 shares during the period. Ananym Capital Management LP acquired a new position in shares of Sotera Health in the fourth quarter valued at approximately $13,680,000. T. Rowe Price Investment Management Inc. increased its stake in shares of Sotera Health by 5.9% in the first quarter. T. Rowe Price Investment Management Inc. now owns 8,045,502 shares of the company’s stock valued at $93,811,000 after buying an additional 450,761 shares during the period. Finally, Two Seas Capital LP increased its stake in shares of Sotera Health by 14.7% in the first quarter. Two Seas Capital LP now owns 3,321,136 shares of the company’s stock valued at $38,724,000 after buying an additional 425,000 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analysts Set New Price Targets

SHC has been the subject of several recent research reports. Barclays reaffirmed an “overweight” rating on shares of Sotera Health in a research note on Friday, August 8th. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Insider Transactions at Sotera Health

In other news, Director Pincus & Co. Warburg sold 12,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $15.11, for a total transaction of $181,320,000.00. Following the completion of the sale, the director owned 61,822,952 shares of the company’s stock, valued at $934,144,804.72. This trade represents a 16.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $15.11, for a total transaction of $120,880,000.00. Following the sale, the director directly owned 41,215,301 shares of the company’s stock, valued at approximately $622,763,198.11. This trade represents a 16.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,126,611 shares of company stock valued at $304,273,888 in the last quarter. 47.55% of the stock is currently owned by company insiders.

Sotera Health Stock Performance

NASDAQ:SHC opened at $15.97 on Friday. The company has a market capitalization of $4.54 billion, a PE ratio of 199.65 and a beta of 1.84. The company has a 50 day simple moving average of $14.15 and a two-hundred day simple moving average of $12.53. The company has a debt-to-equity ratio of 4.49, a quick ratio of 2.23 and a current ratio of 2.47. Sotera Health Company has a fifty-two week low of $9.53 and a fifty-two week high of $16.99.

Sotera Health (NASDAQ:SHC) last released its earnings results on Friday, August 8th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.03. The business had revenue of $294.34 million during the quarter, compared to the consensus estimate of $275.81 million. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 EPS. Sotera Health has set its FY 2025 guidance at 0.750-0.820 EPS. Research analysts anticipate that Sotera Health Company will post 0.61 earnings per share for the current year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.